Uncategorized
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics, reporting to Eric Carlson, Ph.D., Aerie’s Vice President of Research and Development. Dr. White